Skip to main content
Premium Trial:

Request an Annual Quote

Genome Quebec, Paradigm, EGeen International, Prediction Sciences, Genaissance


Genome Quebec First to Buy Illumina’s Genotyping Goliath

Genome Quebec has bought one of Illumina’s nameless SNP-genotyping systems, the company said Jan. 9.

The massive unit, which will be located at the newly opened Genome Quebec Innovation Centre, will help the Canadian center contribute data to the International HapMap Project as well as research at Genome Quebec, Genome Canada, McGill University, and other academic centers in the country.

The product costs between $1.5 million and $2 million and comprises Sherlock scanning equipment, GoldenGate assay protocols, LIMS and analytical software, fluid-handling robotics, and access to Sentrix array matrices and reagent supply. [See accompanying story, this page.]


Paradigm offloads peripatetic ParaGen to Canadian Crop Shop

Canadian crop-science company DNA LandMarks has signed a letter of intent to buy Paradigm Genetics’ plant-genotyping unit ParaGen, Paradigm said Jan. 10.

Founded by Celera, ParaGen was initially known as AgGen. In December 2001, Celera passed the business off to Paradigm Genetics in a deal worth around $2.1 million.

Former Paradigm CEO John Ryals said at the time the acquisition would arm Paradigm with a full range of ag-genomics services. Less than one year later, though, the company announced plans to sell the unit as part of cost-cutting efforts. The deal is expected to close mid-February.


EGeen, Prediction Sciences Pen Pharmacogenetics Pact

EGeen International and Prediction Sciences will collaborate to study the pharmacogenetics of the antidepressant Paxil, the companies said Jan. 13.

EGeen will provide the clinical data while Prediction Sciences will supply bioinformatics expertise to determine the genetic basis of patient response to the drug.

Earlier this year, the firms penned a similar deal to study the pharmacogenetics of Celexa, another depression treatment.


Genaissance Licenses HAP Platform to Millennium

Genaissance has licensed its HAP platform to Millennium Pharmaceuticals, the company said Jan. 7.

The agreement is a non-exclusive, multi-year agreement under which Genaissance will receive license fees from Millennium.

Filed under

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.